MedPath

Sofia hCG FIA Field Study

Completed
Conditions
Pregnancy, Early Detection
Registration Number
NCT01803113
Lead Sponsor
Quidel Corporation
Brief Summary

The objective of this field study is to demonstrate the clinical performance of the Sofia hCG FIA Test, using urine specimens from females of childbearing age.

Detailed Description

Subjects presenting for pregnancy testing will provide urine specimens that will be tested with the Sofia hCG FIA test and the comparator pregnancy test that will detect levels of hCG of 20mIU as positive for pregnancy.

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
975
Inclusion Criteria
  • Female subjects of childbearing age, who are being screened for pregnancy and who have signed the informed consent
Exclusion Criteria
  • Subject is post-menopausal.
  • Subject within the past six weeks has experienced any of the following: delivered a newborn; had an abortion or a natural termination (miscarriage); or, received hCG supplements.
  • Subject has had a hysterectomy.
  • Unable to understand and consent to participation.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Determination of presence of hCG in urine1 day

Clinical performance will be based on comparison of Sofia hCG FIA test results to those obtained from an FDA-cleared hCG test.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (5)

NECCR of Massachusetts, LLC

🇺🇸

Fall River, Massachusetts, United States

Jose Castaneda, MD

🇺🇸

Boynton Beach, Florida, United States

New England Center for Clinical Research Fall River,LLC (NECCR)

🇺🇸

Fall River, Massachusetts, United States

Partners In Obstetrics and Gynecology, Inc.

🇺🇸

Pawtucket, Rhode Island, United States

Planned Parenthood Gulf Coast

🇺🇸

Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath